Cases & Deals

Pfizer acquires Vicuron Pharmaceuticals for $1.9 billion

Clients Pfizer, Inc.

Jones Day represented Pfizer in its $1.9 billion acquisition of Vicuron Pharmaceuticals (Nasdaq NM:MICU), a biopharmaceutical company focused on the development of novel anti-infectives for both hospital-based and community-acquired infections.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.